RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

In recent years, non-alcoholic fatty liver disease (NAFLD) has developed rapidly worldwide and has become the main cause of chronic liver disease. With the increase in prevalence, the incidence of ...

Hoag Memorial Hospital Presbyterian, one of Orange County’s largest hospitals, has implemented the latest in liver cancer ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

diabetes and fatty liver disease," he says. "The best alternative is identifying the underlying causes of stubborn weight and ...

Sydney Towle is sharing her cancer journey on social media as a way to connect with and help others. She's currently waiting ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

With top UK-trained consultants and surgeons specialising in paediatric and adult liver care, the centre is equipped to deliver world-class treatment locally, eliminating the need for patients ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

Glasgow, Scotland - 11 November 2024. EnteroBiotix Limited ('EnteroBiotix' or the 'Company'), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome ...